GEN Exclusives

More »

GEN News Highlights

More »
Mar 10, 2008

Avexa to Use Monogram’s Assays in HIV Drug R&D

  • Monogram Biosciences has become the exclusive provider of HIV resistance and tropism-testing technology to support Avexa's  drug discovery and development programs.

    Avexa plans to use Monogram's assays across its virology portfolio including the Phase III evaluation of its lead compound, apricitabine (ATC), a nucleoside reverse transcriptase inhibitor (NRTI) drug.

    Avexa will utilize Monogram's PhenoSense™ GT assay to select patients and optimize background therapy for trials involving approximately 2,000 patients and to monitor response to drug treatment during the studies.

    ATC is a new nucleoside analog that is intended for use in patients who have developed viral resistance to existing drugs. Avexa also has HIV drugs in early development in the CCR5- and integrase- inhibitor classes.



Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...

Unable to get Jobs Listings.

More »

GEN Poll

More » Poll Results »

Biosimilars

Compared to the original biologics, do you think biosimilars run the risks of being less effective and causing more side effects?